Skip to main content
. Author manuscript; available in PMC: 2013 Nov 30.
Published in final edited form as: Neurosci Lett. 2012 Oct 16;531(1):35–39. doi: 10.1016/j.neulet.2012.10.012

Figure 1. Clinical course of MOG-induced EAE in mice treated with CR2-Crry or CR2-fH.

Figure 1

A. Wild type mice were either treated with saline (n=17; black circles) or with CR2-Crry (n=18; open circles) after induction of EAE and the course of disease was monitored for 30 days. Mice were injected with 500 μgs of CR2-Crry on days 7 and 12-post immunization. Disease severity was significantly attenuated in antibody treated mice (day 12 to 30, p<0.01, Student’s t-test). Results shown are the mean of four experiments. B. Same as A except mice received 400μg of CR2-fH on days 7, 9, 11 and 13 (n=7; open circles) or PBS (n=7, black circles). Disease severity was significantly attenuated in CR2-Crry treated mice (day 13 to 30, p=0.05, Student’s t-test). Results shown are the mean of two experiments.